Business Description
Upstream Bio Inc
NAICS : 541714
SIC : 8731
ISIN : US91678A1079
Description
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 113.68 | |||||
Equity-to-Asset | -0.69 | |||||
Debt-to-Equity | -0.01 | |||||
Debt-to-EBITDA | -0.06 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 0.31 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate | -38.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.05 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 63.57 | |||||
9-Day RSI | 52.2 | |||||
14-Day RSI | 44.14 | |||||
3-1 Month Momentum % | -61.13 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 20.9 | |||||
Quick Ratio | 20.9 | |||||
Cash Ratio | 20.29 | |||||
Days Sales Outstanding | 139.85 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -3143.14 | |||||
Net Margin % | -2632.45 | |||||
FCF Margin % | -3601.7 | |||||
ROA % | -14.04 | |||||
ROIC % | -691.81 | |||||
ROC (Joel Greenblatt) % | -2927.14 | |||||
ROCE % | -17.59 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 342.75 | |||||
EV-to-EBIT | -5.45 | |||||
EV-to-EBITDA | -5.46 | |||||
EV-to-Revenue | 171.35 | |||||
EV-to-Forward-Revenue | 60.37 | |||||
EV-to-FCF | -4.76 | |||||
Earnings Yield (Greenblatt) % | -18.35 | |||||
FCF Yield % | -8.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:UPB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Upstream Bio Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 1.057 | ||
EPS (TTM) ($) | -0.823 | ||
Beta | - | ||
3-Year Sharpe Ratio | - | ||
3-Year Sortino Ratio | - | ||
Volatility % | - | ||
14-Day RSI | 44.14 | ||
14-Day ATR ($) | 0.989975 | ||
20-Day SMA ($) | 7.9305 | ||
12-1 Month Momentum % | - | ||
52-Week Range ($) | 6.65 - 29.4599 | ||
Shares Outstanding (Mil) | 53.6 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Upstream Bio Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Upstream Bio Inc Stock Events
Event | Date | Price ($) | ||
---|---|---|---|---|
No Event Data |
Upstream Bio Inc Frequently Asked Questions
What is Upstream Bio Inc(UPB)'s stock price today?
The current price of UPB is $8.41. The 52 week high of UPB is $29.46 and 52 week low is $6.65.
When is next earnings date of Upstream Bio Inc(UPB)?
The next earnings date of Upstream Bio Inc(UPB) is .
Does Upstream Bio Inc(UPB) pay dividends? If so, how much?
Upstream Bio Inc(UPB) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |